and @edgck, If I can male a suggestion, review all of VRS37 posts carefully. This person is an ill informed person who just posts stuff with no clinical correlation
1) Rituximab as a drug has been used in most of these rare conditions when standard lines of treatment have failed or show no improvement. If you do a quick search on pubmed for rituximab in FSGS you will see that there are calls for a randomised controlled study (of which none have been done yet that I am aware of, happy to be corrected). So as such, clinicians are using it in cases to either buy time prior to a transplant or using it in post transplant patients.
2) From the above statement, what DXB are trying to achieve is a first of its kind in the treatment for FSGS. Once this commercialises, it would have been a drug that has been studied in all phase trials and shown to have a beneficial effect, unlike rituximab which has no randomised trials.
if rituximab is a cheaper option, its only observational. There would have to be a proper study done to compare the DXB with Rituximab to show that efficacy is same/better/worse from a price perspective.
So from the box that VRS37 put up, it is only a matter of time before that flowchart is revised once Dimerix hits the market.
DYOR
- Forums
- ASX - By Stock
- DXB
- Ann: Investor Presentation
Ann: Investor Presentation, page-103
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
48.5¢ |
Change
-0.020(3.96%) |
Mkt cap ! $266.8M |
Open | High | Low | Value | Volume |
50.5¢ | 51.5¢ | 47.5¢ | $3.462M | 7.136M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 411017 | 48.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 2652 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 13587 | 0.485 |
6 | 415600 | 0.480 |
2 | 7367 | 0.475 |
4 | 25586 | 0.470 |
4 | 151986 | 0.465 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 3503 | 2 |
0.475 | 10000 | 1 |
0.490 | 108164 | 2 |
0.495 | 113632 | 3 |
0.500 | 53129 | 5 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online